[The enzyme preparation Kirshner Pancreal in the treatment of patients with chronic pancreatitis].

Our objective in this study was investigation into the effectiveness of the enzymic preparation Kirshner Pancreal in 27 patients with chronic pancreatitis. It is shown that against the background of treatment with the above drug patients dispelled the pain syndrome and manifestations of the maldigestion syndrome. The described drug made for normalization of the blood serum content of beta-lipoproteins.

[The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus].

A peroral sugar-reducing preparation gliquidone (glurenorm) was tried in treatment of 66 patients with digestive diseases (peptic ulcer, chronic pancreatitis, cirrhosis of the liver), presenting with diabetes mellitus. The results of the studies made showed glurenorm to be a highly effective preparation in term of both its sugar-reducing effect and its capability to improve energy processes in gastric and duodenal mucosa, pancreacytes, hepatocytes, besides which, it appear to dispel metabolic disturbances and stimulate reparative processes in body organs, improves protein-synthetic processes in the liver, pancreas, mucosa of the gastroduodenal region.

[The use of Smecta for the treatment of the basic digestive tract diseases].

The indices for the gastric contents aggression and protection ratio returned to normal in patients with peptic ulcer and preulcerous condition during the treatment with smekta due to a decrease in proteolytic activity and increase in the synthesis of the mucus protective proteins. Monitoring of intragastric pH in the body of the stomach throughout 24 hours in patients with peptic ulcer of duodenal location revealed significant acid-neutralizing effect of smekta. Patients with nonspecific ulcerous colitis enjoyed freedom of side effects as a result of the use of salofalk and derived full therapeutic benefit from this treatment.

[The use of 3rd-generation antacid preparations for the treatment of patients with nonulcerous dyspepsia and peptic ulcer complicated by reflux esophagitis].

In the present investigation on the treatment of patients with nonulcerous dyspepsia and peptic ulcer, hiatus hernia complicated with reflux esophagitis, a mechanism has been studied of the action of topalkan, a 3rd generation aluminium-magnesium antacid, that involves not only its antacid properties but in an even greater degree the availability of alginic acid in its formula which has antipeptic and protective effect with respect of the mucous membrane of the stomach and esophagus, and provides, together with the magnesium salts, a floating layer of the preparation in the stomach. In grave course of nonulcerous dyspepsia (preulcerous condition) and peptic ulcer complicated by reflux disease of the esophagus topalkan was used in combination with present-day antisecretory preparations pyrenzepine or H2-blockaders of histamine receptors capable of enhancing the antisecretory effect of topalkan as well as endowed with cytoprotective properties with respect of the mucous membrane of the stomach and duodenum promoting healing of erosions and healing and scarring of ulcerous defects.